A systematic review on the efficacy of interferon beta in relapsing remitting multiple sclerosis; comparison of different formulations

International Journal of Pharmacology

Volumn 6, Issue 5, 2010, Pages 638-644

  Nikfar, S ^a   Rahimi, R ^b   Abdollahi, M ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Tehran University of Medical Sciences   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Avonex; Betaferon; Betaseron; Interferon beta; Meta analysis; Rebif; Relapsing remitting multiple sclerosis; Systematic review

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77955767512     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2010.638.644     Document Type: Article

References (24)

1. Darvish-Damavandi, M., S. Nikfar and M. Abdollahi, A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World I. Gastroenterol, 16: 547-553.
2. Durelli, L., E. Verdun, P. Barbero, M. Bergui and E. Versino et al, 2002. Independent Comparison of Interferon (INCOMTN) Trial Study Group. Everyother- day interferon beta-lb versus once-weekly interferon beta-1 a for multiple sclerosis: results of a 2- year prospective randomised multicentre study (INCOMTN). Lancet, 359: 1453-1460.
3. Elahi, B., S. Nikfar, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials. Dig. Dis. Sci., 53: 1278-1284.
4. Etemadifar, M., M. langhorbani and V. Shaygannejad, 2006. Comparison of Betaferon, Avonex and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol. Scand., 113: 283-287.
5. Guo, S., D. Bozkaya, A. Ward, I.A. O'Brien and K. Ishak, 2009. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-la: Modelling the clinical and economic implications. Pharmacoeconomics, 27: 39-53.
6. lacobson, D.L., S.I. Gange, N.R. Rose and N.M. Graham, 1997. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopafhol., 84: 223-243.
7. ladad, A.R., 1998. Randomised Controlled Trials: A Users Guide. BMI Books, London.
8. Khan, O.A., A.C. Tselis, I.A. Kamholz, I.Y. Garbern, RA. Lewis and RP. Lisak, 2001. A prospective, openlabel treatment trial to compare the effect of IFNbeta- 1 a (Avonex), IFNbeta-1 b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsingremitting multiple sclerosis: Results after 18 months of therapy. Mult. Scler., 7: 349-353.
9. Koch-Henriksen, N., P.S. Sorensen, T. Christensen, I. Frederiksen and Danish Multiple Sclerosis Group et al, 2006. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology, 66: 1056-1060.
10. Limmrofh, V., R. Malessa, U.K. Zettl, I. Koehler and QUASIMS Study Group et al, 2007. Quality assessment in multiple sclerosis therapy (QUASIMS): A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. I. Neurol., 254: 67-77.
11. Lublin, F.D. and S.C. Reingold, 1996. Defining the clinical course of multiple sclerosis: Results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology, 46: 907-911.
12. Meyer, O., 2009. Interferons and autoimmune disorders. Loint Bone Spine, 76: 464-473
13. Murray, CI. and A.D. Lopez, 1997. Alternative projections of mortality and disability by cause 1999-2020: Golden burden of disease study. Lancet, 349: 1498-1504.
14. Nikfar, S., R. Rahimi, F. Rahimi, S. Derakhshani and M. Abdollahi, 2008. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis. Colon Rectum., 51: 1775-1780.
15. Nikfar, S., R. Rahimi, A. Rezaie and M. Abdollahi, 2010. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch. Med. Sci., 6: 236-244.
16. Nortvedt, M.W., T. Ruse, K.M. Myhr and H.I. Nyland, 1999. Quality of life in multiple sclerosis measuring the disease effects more broadly. Neurology, 53: 1098-1103.
17. Panitch, H., D.S. Goodin, G. Francis, P. Chang and P.K. Coyle et al, 2002. Evidence of interferon doseresponse: European North American comparative efficacy; university of British Columbia MS/MRI research group. Randomized, comparative study of interferon beta-la treatment regimens in MS: The EVIDENCE Trial. Neurology, 59: 1496-1506.
18. Patti, F., A. Pappalardo, C. Flono, G. Politi, T. Fionlla, E. Reggio and A. Reggio, 2006. Effects of interferon beta-la and -lb over time: 6-year results of an observational head-to-head study. Acta Neurol. Scand., 113: 241-247.
19. Rahimi, R., S. Nikfar and M. Abdollahi, 2007a. Metaanalysis technique confirms the effectiveness of anti- TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids. Med. Sci. Monit, 13: 13-18.
20. Rahimi, R., S. Nikfar and M. Abdollahi, 2007b. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohns disease? A systematic meta-analysis of controlled clinical trials. Biomed. Pharmacother., 61: 75-80.
21. Rahimi, R., S. Nikfar and M. Abdollahi, 2008a. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12 week trials. Clin. Thera., 30: 884-901.
22. Rahimi, R, S. Nikfar, F. Rahimi, B. Elahi, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008b. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohns disease. Dig. Dis. Sci., 53: 2524-2531.
23. Rahimi, R., S. Nikfar and M. Abdollahi, 2008c. Selective serotonin reuptake inhibitors for the managementof irritable bowel syndrome: A meta- analysis of randomized controlled trials. Arch. Med. Sci., 4: 71-76.
24. Vosoughi, R. and M.S. Freedman, 2010. Therapy of MS. Clin. Neurol. Neurosurg., 112: 365-385.